In partnership with
Profound Medical Corp (TSX: PRN)
When it all clicks.
Why does business news feel like it’s written for people who already get it?
Morning Brew changes that.
It’s a free newsletter that breaks down what’s going on in business, finance, and tech — clearly, quickly, and with enough personality to keep things interesting. The result? You don’t just skim headlines. You actually understand what’s going on.
Try it yourself and join over 4 million professionals reading daily.
Quick Take: Profound Medical is a Canadian medical device company focused on incision-free, MRI-guided therapies, with its flagship TULSA-PRO system targeting prostate disease treatment. While still in growth mode and not yet profitable, the company is entering a critical commercialization phase—one that analysts believe could unlock substantial upside over the next few years.
What Happened This Week?
Stock price jumped 4.0% to $10.62, outperforming both the healthcare industry and broader market.
Shares continue to trade near the upper end of their 52-week range, signaling improving sentiment.
Investor focus remains on accelerating revenue growth, expanding system placements, and improving operating leverage.
This week’s move reflects growing confidence in Profound Medical’s commercialization trajectory rather than short-term news flow.
Key Metrics Snapshot
Metric | Value |
|---|---|
Stock Price | $10.62 |
Weekly Move | +4.02% |
Market Cap | $282M |
P/E Ratio | N/A (pre-profit) |
Forward P/E | N/A |
52-Week Range | $5.23 – $12.40 |
YTD Return | -1.8% |
Dividend Yield | None |
Advertise with Wealth Awesome
Want to get in front of our audience of 20,000+ savvy Canadians ?
⭐ Analyst Insights & Ratings
Consensus Rating: STRONG BUY ⭐⭐⭐⭐☆
Recommendation | Count |
|---|---|
Strong Buy | 3 |
Buy | 1 |
Hold | 0 |
Sell | 0 |
Average Target Price: $17.55
Upside Potential: +65% from current levels
Analysts are bullish due to Profound’s explosive revenue growth outlook, strong balance sheet, and differentiated medical technology.
Recent News Highlights
Commercial momentum building for the TULSA-PRO system as adoption expands across North America.
Revenue guidance implies triple-digit growth, driven by higher system utilization and consumable sales.
Analysts continue to highlight Profound’s strong cash position and low debt as key advantages in a high-rate environment.
Growth Indicators to Watch
Growth Metric | Estimate |
|---|---|
Sales Growth (Next Year) | 108% |
EPS Growth (Next Year) | N/A (loss-making phase) |
5-Year EPS Growth Estimate | 11.4% |
Gross Margin | 72.5% |
Net Cash Per Share | $0.95 |
Despite current losses, Profound Medical’s gross margins and revenue trajectory suggest a clear path toward operating leverage as scale improves.
⚠️ Risk Check (The Trade-Off)
Still unprofitable, with negative margins
Execution risk tied to hospital adoption cycles
Volatility typical of small-cap growth stocks
That said, the company’s low debt, strong liquidity, and rapid sales growth help offset these risks.
Bottom Line
Profound Medical is not a defensive stock—it’s a high-conviction growth bet on medical technology adoption. With analysts forecasting over 100% revenue growth next year and more than 60% upside, PRN stands out as one of the more compelling TSX growth opportunities for patient investors willing to ride volatility.
For investors focused on the next 2–3 years, this is a stock worth watching closely.
Advertise with Wealth Awesome
Want to get in front of our audience of 20,000+ savvy Canadians ?
The Wealth Awesome Team